Prognosis and Management of Pancreaticobiliary Liver Metastases

Introduction to Prognostic Factors

Patients with intrahepatic cholangiocarcinoma (iCCA) and liver metastases have significantly worse prognosis than those with solitary tumors, regardless of lymph node status, with approximately 4 months longer median overall survival compared to other biliary tract cancers 1

The National Comprehensive Cancer Network (NCCN) recommends surgical resection of both primary and liver metastases for pancreatic NETs when technically feasible, with 10-year overall survival rate of 50.4% and 5-year overall survival ranging from 41% to 100% 2, 3, 4, 5
For unresectable disease with low tumor burden and stable disease, observation with imaging every 3-12 months is appropriate until clinically significant progression, according to the NCCN guidelines 2, 3, 4, 5

The American Society of Clinical Oncology (ASCO) emphasizes the importance of distinguishing tumor histology, as pancreatic NETs have dramatically better outcomes than adenocarcinoma and warrant aggressive surgical approaches 2, 3
The American College of Physicians (ACP) recommends early referral to palliative care services at diagnosis, rather than waiting for end-stage disease, with a focus on quality of life and symptom management 6, 7, 8

Patients with pancreatic cancer have one of the highest rates of venous thromboembolism among all malignancies, which is the second leading cause of death after the cancer itself, according to the American Society of Clinical Oncology (ASCO) 6, 7, 8